➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Dow
Medtronic
Boehringer Ingelheim
Colorcon

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205437


Email this page to a colleague

« Back to Dashboard

NDA 205437 describes OTEZLA, which is a drug marketed by Amgen Inc and is included in one NDA. It is available from three suppliers. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the OTEZLA profile page.

The generic ingredient in OTEZLA is apremilast. There are twenty-eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the apremilast profile page.
Summary for 205437
Tradename:OTEZLA
Applicant:Amgen Inc
Ingredient:apremilast
Patents:11
Formulation / Manufacturing:see details
Pharmacology for NDA: 205437
Suppliers and Packaging for NDA: 205437
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OTEZLA apremilast TABLET;ORAL 205437 NDA Amgen Inc 55513-137 55513-137-28 1 BLISTER PACK in 1 CARTON (55513-137-28) > 28 TABLET, FILM COATED in 1 BLISTER PACK
OTEZLA apremilast TABLET;ORAL 205437 NDA Amgen Inc 55513-137 55513-137-50 500 TABLET, FILM COATED in 1 BOTTLE (55513-137-50)
Paragraph IV (Patent) Challenges for 205437
Tradename Dosage Ingredient NDA Submissiondate
OTEZLA TABLET;ORAL apremilast 205437 2018-03-22

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Mar 21, 2014TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Apr 10, 2023
Regulatory Exclusivity Use:INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
Regulatory Exclusivity Expiration:Jul 19, 2022
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
Regulatory Exclusivity Expiration:Jul 19, 2026
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE

Expired US Patents for NDA 205437

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 ⤷  Free Forever Trial ⤷  Free Forever Trial
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 ⤷  Free Forever Trial ⤷  Free Forever Trial
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Express Scripts
Boehringer Ingelheim
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.